about
Non-Medical Risk Factors as Avoidable Determinants of Excess Mortality in Children with Chronic Kidney Disease. A Prospective Cohort Study in Nicaragua, a Model Low Income CountryAn open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediEpidemiology of chronic renal failure in children: data from the ItalKid project.Treatment data during pediatric home peritoneal teledialysis.Role of non-polio enterovirus infection in pediatric hemolytic uremic syndrome.Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome.Genetic risk factors in typical haemolytic uraemic syndrome.Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome.Isolation in Italy of a verotoxin-producing strain of Escherichia coli O157:H7 from a child with hemolytic-uraemic syndrome.Skin involvement in atypical hemolytic uremic syndrome.Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality.Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization.Severe and isolated headache associated with hypertension as unique clinical presentation of posterior reversible encephalopathy syndrome.Rituximab in children with resistant idiopathic nephrotic syndrome.Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.A review on JC virus infection in kidney transplant recipients.Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations.Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndromeAssessment of nutritional status in children with chronic kidney disease and on dialysis.Febrile urinary tract infections: clinical and laboratory diagnosis, imaging, and prognosis.Plasma-exchange in pediatric patients: a single-center experience.Pleuro-peritoneal or pericardio-peritoneal leak in children on chronic peritoneal dialysis-A survey from the European Paediatric Dialysis Working Group.Social and economic determinants of pediatric health inequalities: the model of chronic kidney disease.Antithrombotic prophylaxis in a patient with nephrotic syndrome and congenital protein S deficiency.Deciphering Variability of PKD1 and PKD2 in an Italian Cohort of 643 Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients.A case study: telemedicine technology and peritoneal dialysis in children.Chronic haemodialysis in small children: a retrospective study of the Italian Pediatric Dialysis Registry.The acute interstitial nephritis induced by azithromycin.Nutcracker phenomenon and idiopathic IgA nephropathy.Bioimpedance and Fluid Status in Children and Adolescents Treated With Dialysis.Hemodialysis in children with ventriculoperitoneal shunts: prevalence, management and outcomes.Reduction in catheter-related infections after switching from povidone-iodine to chlorhexidine for the exit-site care of tunneled central venous catheters in children on hemodialysis.Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults.Adenine phosphoribosyltransferase deficiency: an underdiagnosed cause of lithiasis and renal failure.Similarity of Shiga toxin-producing Escherichia coli O104:H4 strains from Italy and Germany.Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers.Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.
P50
Q30384519-63E77491-2C1A-41B0-ADEB-4E7972285F07Q30395254-C2EA3B37-24CE-4957-A21E-6C016B96D325Q30782955-EADB0481-26AA-4E43-906D-6B52FB80C7DEQ30789669-77E6F710-5B5D-48A9-9D83-568924BAB2E2Q33344666-F3DA4C30-F6A1-40C0-BC79-2BFD6FB27172Q33357383-6D5D28D5-4936-481D-98DC-212B915B67A6Q33370181-A5C00C41-1B58-49C5-BEA2-5AEC5141EE2FQ33382580-187E8ED6-F1F2-46C5-B5D2-3D2AB85880EBQ33393331-7369D245-938A-4D8D-9EB7-72D023B55B96Q33396996-27A8F9F6-CBE2-4C68-95DD-6C9E1D1E820FQ33411798-B3847B84-B7EE-4148-8C48-74A02FA06E3FQ34558874-84247735-E54C-45CE-8EE6-E4F73029C8ABQ35030581-87B16EB8-4B5C-4A72-BDB0-DF17D58C042CQ35168576-75CC02B2-08D4-491C-B85B-A6EC550470B3Q35213287-741A2375-A989-4575-9F36-560490FB32EBQ35982341-92FF905D-7709-4838-923B-0ED6B425D4D1Q36003160-55C735C7-9D7A-4714-8383-B61926F54022Q36602840-08023A1D-0605-4811-B970-9C68C6470794Q37211071-AF41E8EC-D95A-444C-B0F2-DDE4C9B5A4E2Q37275486-857637F3-82B6-44A8-B434-4120BB22F33EQ38134289-2E0FE92D-37F8-40F2-87DC-7273C041E753Q38184000-82FCD964-8E1F-42DD-820B-78B25DC2F4E4Q38269892-BFFBB8E7-7785-4827-93D8-E5EDB78251DEQ38520888-43DF224C-D79E-4B24-8483-CC0A4CD5CD35Q38606888-2F831169-E178-4D2E-9847-CCA05D5C80FDQ38673228-9B311509-962A-4483-8507-5EB98A57FE76Q39514878-E1E1CAE4-0BA7-4705-B239-3069D04CA4A1Q39591103-875F1479-5A88-46A0-A14A-2005BEE486B3Q39643766-AEC1C7A5-15F9-4CF5-9E2A-92D2FEAD1640Q40183569-E7C48212-5F94-4EBE-97D1-C5116C904155Q40335656-A7388592-403A-4762-84E6-A38EA8E17005Q40337427-A1187A82-BCE0-49F5-B053-DFDB17F6B021Q40380239-48D5EA45-C60B-47E4-BF6D-541EE6CA7033Q40522420-E2E8358E-6D7B-43E8-AAC2-4B3F113F0EB6Q41694674-D39E1176-7C0E-4667-AF50-BABA3967070DQ42209552-DE684189-E41F-4A14-8A0B-3838E4A4FC98Q42368262-8E8A5476-A808-441B-9D23-8FF8EFD3681AQ42572253-F36D341A-DDED-4AA5-B1CC-0FC5272946F7Q42780140-A63AE6A7-A5C1-4658-8605-268F0197DD54Q43018708-473498CB-837A-4493-B4D1-9C7D093BB929
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alberto Edefonti
@ast
Alberto Edefonti
@en
Alberto Edefonti
@es
Alberto Edefonti
@nl
Alberto Edefonti
@sl
type
label
Alberto Edefonti
@ast
Alberto Edefonti
@en
Alberto Edefonti
@es
Alberto Edefonti
@nl
Alberto Edefonti
@sl
prefLabel
Alberto Edefonti
@ast
Alberto Edefonti
@en
Alberto Edefonti
@es
Alberto Edefonti
@nl
Alberto Edefonti
@sl
P1053
I-6964-2015
P106
P21
P31
P3829
P496
0000-0003-3106-4915